Core Insights - IMUNON, Inc. is advancing its lead candidate IMNN-001 in a Phase 3 clinical trial for newly diagnosed advanced ovarian cancer, with the first trial site initiated for the OVATION 3 study [5][6] - The Phase 2 OVATION 2 study data has been accepted for oral presentation at the 2025 ASCO Annual Meeting, highlighting the potential of IMNN-001 in improving patient outcomes [8][9] - The company reported a net loss of $4.1 million for Q1 2025, a decrease from $4.9 million in Q1 2024, indicating improved financial management [15][18] Recent Developments - The initiation of the first trial site for the OVATION 3 study is a significant milestone in the development of IMNN-001, which aims to provide a new treatment option for women with advanced ovarian cancer [5][6] - The OVATION 2 study demonstrated that IMNN-001, when combined with chemotherapy, is the first immunotherapy to extend both progression-free and overall survival in newly diagnosed ovarian cancer patients [3][4] - New translational data from the OVATION 2 study showed a 20% increase in IL-12 levels in patients treated with IMNN-001 compared to those receiving a lower dose, reinforcing the drug's mechanism of action [10] Financial Performance - For Q1 2025, operating expenses were reported at $4.1 million, down 18% from $5.0 million in Q1 2024, primarily due to reduced R&D costs [15][16] - Research and development expenses decreased to $2.2 million in Q1 2025 from $3.3 million in Q1 2024, reflecting lower costs associated with ongoing clinical trials [16] - As of March 31, 2025, the company had cash and cash equivalents of $2.9 million, which is expected to fund operations into late Q2 2025 [18] Clinical Trials and Research - The Phase 3 OVATION 3 trial will evaluate the safety and efficacy of IMNN-001 in combination with neoadjuvant and adjuvant chemotherapy compared to standard care [6] - The study will include women with newly diagnosed advanced ovarian cancer, focusing on overall survival as the primary endpoint [6] - Data from the OVATION 2 study will be published in the peer-reviewed journal Gynecologic Oncology, further validating the findings of the trial [7]

Core Insights - Avalo Therapeutics, Inc. is making significant progress in its Phase 2 LOTUS trial for AVTX-009, targeting hidradenitis suppurativa (HS), with topline data expected in 2026 [2][5] - The company has sufficient capital, approximately $125 million as of March 31, 2025, to fund operations into at least 2027, with potential to extend into 2028 [5][6] - The company is evaluating additional development activities beyond the LOTUS trial, considering current market conditions [2][5] Financial Performance - Cash and cash equivalents were reported at $125.0 million as of March 31, 2025, down from $134.5 million at the end of 2024 [7] - Net cash used in operating activities for Q1 2025 was $9.5 million, with research and development expenses increasing to $9.1 million, up from $2.1 million in Q1 2024 [6][9] - The net loss for Q1 2025 was $13.1 million, a significant decrease from $121.3 million in Q1 2024, primarily due to a reduction in other expenses related to prior period warrants [6][9] Trial and Development Updates - The LOTUS trial involves approximately 180 adults with HS, evaluating the efficacy and safety of AVTX-009 with expected topline data in 2026 [6][12] - The primary efficacy endpoint is the proportion of subjects achieving Hidradenitis Suppurativa Clinical Response (HiSCR75) at Week 16 [12] - Avalo is also exploring AVTX-009 for additional immune-mediated diseases and plans to announce a second indication [6][12] Corporate Highlights - Mike Heffernan has been appointed as Chairman of the Board [5] - The company continues to focus on its lead asset, AVTX-009, which targets inflammatory diseases by neutralizing interleukin-1β [10][11]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sana Biotechnology, Inc. regarding a class action lawsuit due to allegations of misleading statements and financial misrepresentation during a specified class period [1][2]. Group 1: Allegations - The complaint alleges that during the class period from March 17, 2023, to November 4, 2024, Sana Biotechnology was at significant risk of having insufficient funds to maintain its operations and advance its product candidates [1]. - It is claimed that product candidates SC291 in oncology, SC379, and SG299 were less promising than what the defendants had communicated to investors [1]. - The company is likely to decrease funding for or discontinue certain product candidates and significantly reduce its workforce to preserve cash for more promising projects [1]. - The defendants allegedly overstated Sana's financial capacity to maintain operations and advance existing product candidates, leading to materially false and misleading public statements [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares of SANA during the specified timeframe are encouraged to register for the class action, with a deadline of May 20, 2025, to seek lead plaintiff status [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements or omissions that led to artificial inflation of stock prices [3].

Core Insights - Jeito Capital has promoted Mehdi Ainouche to Partner and Julien Elric to Senior Principal, reflecting the firm's growth and commitment to internal talent development [1][6] Group 1: Promotions and Roles - Mehdi Ainouche joined Jeito in 2020 and has played a crucial role in the investment cycle, particularly with the successful sale of EyeBio to Merck & Co for up to $3 billion [2][3] - Julien Elric joined Jeito in 2021 and has been instrumental in financing and clinical development strategies, notably contributing to the investment and exit of HI-Bio acquired by Biogen Inc. for up to $1.8 billion [4][5] Group 2: Company Overview - Jeito Capital is a leading global Private Equity fund focused on biopharma, dedicated to financing and accelerating medical innovations with a patient benefit-driven approach [7] - The firm has built a diversified portfolio of clinical biopharmas addressing high unmet medical needs, with a presence in Europe and the United States [7]

Company Overview - Jeito Capital is a leading independent Private Equity fund focused on biopharma, dedicated to financing and accelerating the development of groundbreaking medical innovations [7] - The firm has a diversified portfolio of clinical biopharmas that address high unmet medical needs, with a strong presence in Europe and the United States [7] Promotions and Team Development - Mehdi Ainouche has been promoted to Partner, and Julien Elric to Senior Principal, reflecting Jeito's commitment to talent development and internal career progression [1][6] - Mehdi joined Jeito in 2020 and has played a crucial role in the investment cycle, particularly noted for the successful sale of EyeBio to Merck & Co for up to $3 billion [2] - Julien joined Jeito in 2021 and has been instrumental in financing and clinical development strategies, contributing to the investment and exit of HI-Bio™ acquired by Biogen Inc. for up to $1.8 billion [4] Leadership Insights - Dr. Rafaèle Tordjman, Founder and CEO of Jeito Capital, expressed delight in the promotions, highlighting the significant contributions of Mehdi and Julien to the firm's mission of unlocking the potential of portfolio companies [6]

Core Viewpoint - Recursion Pharmaceuticals experienced a significant stock decline of 24% following disappointing first-quarter earnings and concerns over federal research funding cuts impacting the biotech industry [1][2][3]. Financial Performance - Recursion reported an earnings-per-share (EPS) loss of $0.50 on sales of $14.75 million, slightly beating Wall Street's expectations but falling short of the forecasted sales of $14.98 million [2]. Development Pipeline - The company announced it would reduce its development pipeline significantly to cut costs, indicating a strategic shift in its research focus [2][4]. Industry Challenges - The Trump administration's proposed cuts to the National Institutes of Health (NIH) and other research funding sources are expected to make capital raising more difficult for biotech firms, as indicated by a survey of industry leaders [3]. Long-term Viability - Recursion is heavily investing in research and development while operating at a loss, suggesting that it will require external funding to sustain its operations and achieve long-term profitability [4]. Investment Outlook - Despite the potential of Recursion's innovative use of AI in drug discovery, the company faces significant uncertainty, making it a suitable investment only for aggressive, risk-tolerant investors [5].

SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. Business Highlights Surrozen has pivoted its focus to its ophthalmology pipeline, leveraging its Wnt biolog ...

Group 1: BioCryst Pharmaceuticals, Inc. (BCRX) - BioCryst has a Zacks Rank 1 and the Zacks Consensus Estimate for its current year earnings increased by 285.7% over the last 60 days [1] - The company's shares gained 15% over the last three months, while the S&P 500 declined by 7.2% [1] - BioCryst possesses a Momentum Score of A [1] Group 2: WidePoint Corporation (WYY) - WidePoint has a Zacks Rank 1 and the Zacks Consensus Estimate for its current year earnings increased by 108.3% over the last 60 days [2] - The company's shares gained 35.7% over the last three months, compared to the S&P 500's decline of 7.2% [2] - WidePoint possesses a Momentum Score of B [2] Group 3: Rambus Inc. (RMBS) - Rambus has a Zacks Rank 1 and the Zacks Consensus Estimate for its current year earnings increased by 3.9% over the last 60 days [3] - The company's shares gained 11.6% over the past month, while the S&P 500 advanced by 6.9% [3] - Rambus possesses a Momentum Score of B [3]

Rapid Micro Biosystems (RPID) Q1 2025 Earnings Call May 09, 2025 08:30 AM ET Company Participants Michael Beaulieu - Vice President of Investor Relations & Corporate CommunicationsSean Wirtjes - Chief Financial OfficerDan Arias - Managing DirectorRobert Spignesi - CEO, President & DirectorPaul Knight - Managing DirectorChad Wiatrowski - VP - Equity Research Operator Thank you for standing by. My name is RG, and I will be your conference operator today. At this time, I would like to welcome everyone to the R ...

Group 1 - Chain Bridge Bancorp, Inc. (CBNA) has seen a 9.5% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Fresenius Medical Care AG (FMS) has experienced a 4.5% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Brenntag SE (BNTGY) has seen a 14.1% increase in the Zacks Consensus Estimate for its next year earnings over the last 60 days [2] - WidePoint Corporation (WYY) has experienced a significant 108.3% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - BioCryst Pharmaceuticals, Inc. (BCRX) has seen an impressive 285.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [3]